[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351682-105":59,"doc-detail-351682-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","trim11-is-upregulated-in-esophageal-cancer-research-article","TRIM11 is upregulated in esophageal cancer - Research article","","Esophageal cancer is a prevalent malignancy with limited treatment options. Emerging evidence indicates that tripartite motif proteins contribute to cancer, yet the role of TRIM11 in esophageal cancer remains unclear. This study combines comprehensive bioinformatics with cell and animal experimental models to define how TRIM11 drives tumor progression and assess its value as a marker linked to adverse clinicopathological features.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/trim11-is-upregulated-in-esophageal-cancer-research-article/351682/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/trim11-is-upregulated-in-esophageal-cancer-research-article/351682.png","ImageObject",300,407,{"name":92,"@type":93},"Cart","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-09-24","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":14},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study designed to determine about TRIM11 in esophageal cancer?","Question",{"text":112,"@type":113},"The study evaluated TRIM11 expression patterns and its contribution to esophageal cancer progression, including underlying molecular mechanisms and potential association with adverse clinical features and treatment response.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was TRIM11 expression assessed in the research?",{"text":117,"@type":113},"Transcriptomic analyses were performed using publicly available datasets including TCGA, GTEx, CCLE, and other sources to examine TRIM11 levels and correlations with clinicopathological factors, immune infiltration, and treatment response.",{"name":119,"@type":110,"acceptedAnswer":120},"What mechanistic pathway is linked to TRIM11’s effects in esophageal cancer?",{"text":121,"@type":113},"Mechanistic experiments showed that TRIM11 directly interacts with Axin2 and GSK3β, core components of the β-catenin destruction complex, and affects key β-catenin pathway proteins such as CyclinD1, GSK3β, Axin2, and β-catenin.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},351682,1790269096,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":14,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},18829141979164,"https://eur-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Functional & Integrative Genomics (2026) 26:101 [https://doi.org/10.1007/s10142-026-01880-6](https://doi.org/10.1007/s10142-026-01880-6)  \nRESEARCH  \nTRIM11 is upregulated in esophageal cancer and promotes tumor progression through modulation of the β-catenin signaling pathway  \nWei Li1,2 · Qingzhi Lan2,4 · Shimin Lu2,4 · Weiguo Dong1,3  \nReceived: 8 February 2026 / Revised: 4 April 2026 / Accepted: 4 May 2026 © The Author(s) 2026  \nAbstract  \nEsophageal cancer (EC) is a frequently diagnosed malignancy with limited available treatment options. Emerging evidence has underscored the significant role of tripartite motif (TRIM) proteins in various cancers. However, the specific role of TRIM11 in EC has not been elucidated. Here, we conducted a comprehensive bioinformatics analysis, along with cell line models and animal culture experiments, to investigate the role of and molecular mechanisms through which TRIM11 contributes to EC progression, and evaluate its potential as a candidate marker associated with adverse clinicopathological features. Transcriptomic analysis was conducted using data from TCGA, GTEx, CCLE, and other publicly available databases to assess TRIM11 expression and its correlation with clinicopathological features, immune infiltration and TRIM11’s relationship with treatment response in EC. In vitro experiments showed that TRIM11 overexpression significantly promoted EC cell proliferation, migration, and invasion. Flow cytometry analysis revealed that TRIM11 increased the proportion of cells entering the S phase. Mechanistically, co-immunoprecipitation assays demonstrated that endogenous TRIM11 directly interacted with Axin2 and GSK3β, two core components of the β-catenin destruction complex. Additionally, TRIM11 knockdown altered the expression of key proteins in the β-catenin signaling pathway, including CyclinD1, GSK3β, Axin2, and β-catenin. Collectively, these findings highlight TRIM11 as a pro-oncogenic factor and suggest that it is a potential functional driver of EC.  \nKeywords Esophageal cancer · TRIM11 · β-catenin pathway · Immune infiltration  \nIntroduction  \nEsophageal cancer (EC) is a prevalent malignancy originating from the esophageal epithelium and primarily includes esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) . According to global epidemiological data from 2022, EC ranks seventh among the  \n􀀍 Weiguo Dong [dongweiguo@whu.edu.cn](dongweiguo@whu.edu.cn)  \n1 Department of Gastroenterology, Renmin Hospital of Wuhan University, No. 238 Zhang Zhi-dong Road, Wuhan 430060, China  \n2 Central Laboratory, Renmin Hospital of Wuhan University, Wuhan, China  \n3 Key Laboratory of Hubei Province for Digestive System Disease, Wuhan, China  \n4 Department of Pathology, Renmin Hospital of Wuhan University, Wuhan, China  \nleading causes of cancer-related deaths (4.6% of all cancerrelated deaths) (Bray et al. 2024). In China, EC remains oneof the deadliest malignancies, with an estimated 193,290 deaths reported in the most recent statistics (Wu et al. 2024) . Survival is low in EC (20%) (Siegel et al. 2021) . Strong malignancy and the absence of specific early clinical symptoms result in most patients being diagnosed at advanced stages. For locally advanced EC, neoadjuvant therapy (chemotherapy and/or radiotherapy) is recommended to downstage the tumor and control micrometastatic disease in order to improve clinical outcomes. Despite improvements in neoadjuvant regimens, surgical techniques, and patientselection, the 5-year recurrence-free survival (RFS) rate following subsequent esophagectomy remains at approximately 50%(Sho Okuda 2023) . Therefore, the molecular mechanisms that drive EC progression must be urgently elucidated to develop novel and effective therapeutic strategies for patients with advanced disease.  \nThe tripartite motif (TRIM) protein family, characterized by an N-terminal TRIM region that includes a RING finger  \ndomain, predominantly functions as E3 ubiquitin ligas","cbCaiucwTAQ8BD35","https://ap.wps.com/l/cbCaiucwTAQ8BD35","pdf",6515238,18,"English","# Abstract\n# Introduction\n## Background and clinical challenge in esophageal cancer\n## TRIM protein family and oncogenic roles\n## Prior evidence linking TRIM11 to multiple cancers","[{\"question\":\"What was the study designed to determine about TRIM11 in esophageal cancer?\",\"answer\":\"The study evaluated TRIM11 expression patterns and its contribution to esophageal cancer progression, including underlying molecular mechanisms and potential association with adverse clinical features and treatment response.\"},{\"question\":\"How was TRIM11 expression assessed in the research?\",\"answer\":\"Transcriptomic analyses were performed using publicly available datasets including TCGA, GTEx, CCLE, and other sources to examine TRIM11 levels and correlations with clinicopathological factors, immune infiltration, and treatment response.\"},{\"question\":\"What mechanistic pathway is linked to TRIM11’s effects in esophageal cancer?\",\"answer\":\"Mechanistic experiments showed that TRIM11 directly interacts with Axin2 and GSK3β, core components of the β-catenin destruction complex, and affects key β-catenin pathway proteins such as CyclinD1, GSK3β, Axin2, and β-catenin.\"}]","TRIM11 is upregulated in esophageal cancer - Research article | PDF",1790095278,45]